Wissenschaftliche Arbeiten

Doç. Dr. Nalan Akgül Babacan

63 Publikationen. Neben jeder Publikation steht die Quelle der Angabe.

Zurück zum Profil

  1. Ozkan, K., Turkkan, E., Ender, K., Mutlu, D., Murat, A., Nalan, B., A Yıldız, Osman, M. (2005). 5-Fluorouracil, epirubicin and cisplatin in the treatment of metastatic gastric carcinoma: a retrospective analysis of 68 patients. Indian Journal of cancer, 42(2), 85.

    Quelle: Profilseite auf medicana.com.tr

  2. Odabas, H., Ozdemir, N., Isik, M., Abali, H., Oksuzoglu, B., Kos, T., B. Civelek, A.N. Babacan, U. Dogan, Zengin, N. (2010). Safety and efficacy of FOLFIRI-bevacizumab for metastatic colorectal carcinoma as second line treatment. Journal of BU ON: official journal of the Balkan Union of Oncology, 16(3), 460-463.

    Quelle: Profilseite auf medicana.com.tr

  3. Cihan, S., Uncu, D., Babacan, N. A., Özdemir, N., Odabaş, H., Aksoy, S.,Oksuzoglu B, Zengin, N. (2011). Adjuvant modified FOLFOX-4 in patients with stage III rectum adenocarcinoma. Asian Pac J Cancer Prev, 12(4), 967-970.

    Quelle: Profilseite auf medicana.com.tr

  4. Kesikli, S. A., Eren, M. F., Akgul Babacan, N., & Kilickap, S. (2012). Prognosis of colorectal cancer with peritoneal carcinomatosis: Is a new staging necessary? Journal of Clinical Oncology, 30(18), 2287-2288.

    Quelle: Profilseite auf medicana.com.tr

  5. Babacan, N. A., Aksoy, S., Cetin, B., Ozdemir, N. Y., Benekli, M., Uyeturk, U., M. Ali Kaplan, T. Kos, H. Karaca, B. Oksuzoglu, N. Zengin, S. Buyukberber (2012). Multiple primary malignant neoplasms: Multi-center results from Turkey. J BUON, 17(4), 770-5.

    Quelle: Profilseite auf medicana.com.tr

  6. Demirci, U., Ozdemir, N., Benekli, M., Babacan, N. A., Cetin, B., Baykara, M., U. Coskun, N. Zengin, Buyukberber, S. (2012). Lymphoproliferative disorders in multiple primary cancers. Asian Pacific Journal of Cancer Prevention, 13(1), 383-386.

    Quelle: Profilseite auf medicana.com.tr

  7. Budakoğlu, B., Aksoy, S., Arslan, Ç., Üyetürk, Ü., Babacan, N. A., Özcan, M. F., Ozcan, R. Yıldız, B.B. Oven, N.Y. Ozdemir, O. Dizdar, Büyükberber, S. (2012). Frequency of HCV infection in renal cell carcinoma patients. Medical Oncology, 29(3), 1892-1895.

    Quelle: Profilseite auf medicana.com.tr

  8. Seker, M. M., Sancaktar, E., Acibucu, D. O., Filiz, A. K., Deveci, K., Bahceci, A., Kaçan T, Babacan N, Yuce, S. (2013). Prognostic value of serum Tie-2 and vascular endothelial growth factor levels in cancer patients. Eur Rev Med Pharmacol Sci, 17(21), 2929-2932.

    Quelle: Profilseite auf medicana.com.tr

  9. Babacan, N. A., Yucel, B., Kilickap, S., Seker, M. M., Kacan, T., Olcas, I. K., Eren A.A., Odabas, H. (2013). Lung cancer in women: a single institution experience with 50 patients. Asian Pacific journal of cancer prevention: APJCP, 15(1), 151-154.

    Quelle: Profilseite auf medicana.com.tr

  10. Yucel, B., Babacan, N. A., Kacan, T., Eren, A. A., Eren, M. F., Bahar, S., Celasun, M. G., Seker M.M, Hasbek, Z. (2013). Survival analysis and prognostic factors for neuroendocrine tumors in Turkey. Asian Pacific Journal of Cancer Prevention, 14(11), 6687-6692.

    Quelle: Profilseite auf medicana.com.tr

  11. Bilici, A., Inanc, M., Ulas, A., Akman, T., Seker, M., Babacan N. A., A. İnal, , Bal O., Koral L., Sevinç A., Tufan G., Elkıran E.T., Oven Ustaalioglu B.B., Yavuzsen T., Alkıs N., Ozkan M., Gumus M.. (2013). Clinical and pathologic features of patients with rare ovarian tumors: multi-center review of 167 patients by the anatolian society of medical oncology. Asian Pacific Journal of Cancer Prevention, 14(11), 6493-6499.

    Quelle: Profilseite auf medicana.com.tr

  12. Yetisyigit, T., Babacan, N., Urun, Y., Seber, E. S., Cihan, S., Arpaci, E., N. Yıldırım, S. Aksoy, B. Budakoglu, N. Zengin, B. Oksuzoglu, B. Cicek Yalcın, N. Alkis, (2014). Predictors of outcome in patients with advanced nonseminomatous germ cell testicular tumors. Asian Pac J Cancer Prev, 15(2), 831-5.

    Quelle: Profilseite auf medicana.com.tr

  13. Kacan, T., Babacan, N. A., Seker, M., Yucel, B., Bahceci, A., Eren, Eren A. A., Eren M.F., Kılıckap S. (2014). Could the neutrophil to lymphocyte ratio be a poor prognostic factor for non small cell lung cancers. Asian Pac J Cancer Prev, 15(5), 2089-2094.

    Quelle: Profilseite auf medicana.com.tr

  14. Kilickap, S., Kaya, Y., Yucel, B., Tuncer, E., Babacan, N. A., & Elagoz, S. (2014). Higher Ki67 expression is associates with unfavorable prognostic factors and shorter survival in breast cancer. Asian Pac J Cancer Prev, 15(3), 1381-1385.

    Quelle: Profilseite auf medicana.com.tr

  15. Kacan, T., Altun, A., Altun, G. G., Kacan, S. B., Sarac, B., Seker M. M., Bahceci A, Babacan, N. (2014). Investigation of antitumor effects of sorafenib and lapatinib alone and in combination on MCF-7 breast cancer cells. Asian Pac. J. Cancer Prev, 15(7), 3185-3189.

    Quelle: Profilseite auf medicana.com.tr

  16. Seker, M. M., Yucel, B., Seker, A., Eren, A. A., Bahar, S., Celasun, G.,Kacan T, Eren M.F., Babacan N, Bahceci, A. (2014). Treatment and prognosis of breast cancer in elderly: Different from young patients?. European Geriatric Medicine, 5(4), 261-264.

    Quelle: Profilseite auf medicana.com.tr

  17. Yucel, B., Akkaş, E. A., Okur, Y., Eren, A. A., Eren, M. F., Karapınar, H.,Akgul Babacan N, Kılıçkap, S. (2014). The impact of radiotherapy on quality of life for cancer patients: a longitudinal study. Supportive Care in Cancer, 22(9), 2479-2487.

    Quelle: Profilseite auf medicana.com.tr

  18. Seker, M. M., Sancakdar, E., Seker, A., Bahceci, A., Kacan, T., Babacan, N., S Yuce (2014). Prognostic value of serum TIE-2 and vascular endothelial growth factor levels in gastric cancer patients. (2014): e15085-e15085.

    Quelle: Profilseite auf medicana.com.tr

  19. Seker, M. M., Uslu, A. U., Ozer, H., Seker, A., Kacan, T., Babacan. N.,Aker H, Elagoz, S. (2014). Orbital metastasis of endocervical stromal sarcoma: a rare tumor and an uncommon metastasis. Przeglad menopauzalny= Menopause review, 13(6), 356.

    Quelle: Profilseite auf medicana.com.tr

  20. Yücel, B., Bahar, S., Kaçan, T., Seker, M. M., & Celasun, M. G. Bahceci A., Akgul Babacan N (2014). Importance of metastasis site in survival of patients with breast cancer. Austin J Med Oncol, 1(2), 7.

    Quelle: Profilseite auf medicana.com.tr

  21. Cihan, S., Atasoy, A., Yildirim, Y., Babacan N. A., Kos, T. F. (2014). Hypersensitivity and tumor lysis syndrome associated with cetuximab treatment: should we be afraid?. Tumori, 101(2), e40-5.

    Quelle: Profilseite auf medicana.com.tr

  22. Cihan, S., Odabas, H., Ozdemir, N. Y., Yazilitas, D., Babacan, N. A. (2015). Treatment Approaches in 102 Elderly Patients With Non-Small Cell Lung Cancer. World Journal of Oncology, 6(1), 276-282

    Quelle: Profilseite auf medicana.com.tr

  23. Babacan, N. A., Kiliçkap, S., Sene, S., Kacan, T., Yucel, B., Eren, M. F., Cihan, S. (2015). A case of multifocal skin metastases from lung cancer presenting with vasculitic-type cutaneous nodule. Indian journal of dermatology, 60(2), 213

    Quelle: Profilseite auf medicana.com.tr

  24. Seker, M. M., Deveci, K., Seker, A., Sancakdar, E., Yilmaz, A., Turesin, A. K.,Kacan T, Babacan, N. A. (2015). Predictive role of neutrophil gelatinase-associated lipocalin in early diagnosis of platin-induced renal injury. Asian Pac J Cancer Prev, 16, 407-410.

    Quelle: Profilseite auf medicana.com.tr

  25. Yilmaz, M., Donmez, G., Kacan, T., Sari, I., Babacan N. A., Sari, M., Kilickap, S. (2015). Significant association between polymorphisms of Wnt antagonist genes and lung cancer. Journal of Investigative Medicine, 63(8), 935-941.

    Quelle: Profilseite auf medicana.com.tr

  26. Tanrıkulu Sımsek E., Besiroglu M., Aktas B., Koca S., Halil Suleyman, Alan O., Hasanov R., Akgul Babacan N., Ozturk MA, Kaya S., Ozdogan OC, Dane F., Yumuk PF (2015). Can we restart vemurafenib after severe hepatotoxicity? A case report. JJ Gastro Hepato, 2(4):025.

    Quelle: Profilseite auf medicana.com.tr

  27. Turan, N., Benekli, M., Unal, O. U., Unek, İ. T., Tastekin, D., Dane, F.,Algın E., Ulger S., Eren T., Ozturk Topcu T., Turkmen E., Akgul Babacan N ... & Buyukberber S. (2015) Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma. Chinese Journal of Cancer Research, 27(4), 408.

    Quelle: Profilseite auf medicana.com.tr

  28. Salman, A., Tekin, B., Koca, S., Babacan, N. A., Yumuk, P. F., Ergun, T. (2016). Another adverse effect of vemurafenib: Gingival hyperplasia. The Journal of dermatology, 43(6), 706-707.

    Quelle: Profilseite auf medicana.com.tr

  29. Babacan, N. A., Eğilmez, H. R., Yücel, B., Parlak, I., Şeker, M. M., Kaçan, T., Bahceci A., Cıhan S., Akıncı B., Eriten B., Kılıçkap, S. (2016). The prognostic value of UHRF-1 and p53 in gastric cancer. Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association, 22(1), 25.

    Quelle: Profilseite auf medicana.com.tr

  30. Babacan, N. A. (2016). Will we have a new ending for Irvin Yalom's novel? A medical oncologist view. Journal of Oncological Science, 2(1), 5-6.

    Quelle: Profilseite auf medicana.com.tr

  31. Kacan, T., Yucel, B., Bahar, S., Celasun, G., Seker, M. M., Babacan, N., Bahceci A., Kacan S., Kilickap, S. (2016). The Prognostic Value of High Pretreatment Plasma D-Dimer Levels in Non-Metastatic Breast Cancer Patients with Absence of Venous Thromboembolism. International Journal of Hematology and Oncology, 26(4), 136-144.

    Quelle: Profilseite auf medicana.com.tr

  32. Kacan, T., Nayir, E., Altun, A., Kilickap, S., Babacan, N. A., Ataseven, H., Kaya, T. (2016). Antitumor activity of sorafenib on colorectal cancer. Journal of Oncological Sciences, 2(2), 53-57.

    Quelle: Profilseite auf medicana.com.tr

  33. Kaya S, Aktas B, Tanrikulu Simsek E, Akif Ozturk M, Dede F, Kaya H, Ugurlu U, Ozgen Z, Koca S, Halil S, Hasanov R, Alan O, Akgul Babacan N, Ercelep O, Dane F, Gumus M, Yumuk F.(2017). Changes in 18F-FDG-PET/CT tumor metabolism are not consistent with pathologic complete response in hormone-positive breast cancer. J BUON. 2017 Sep-Oct;22(5):1191-1198.

    Quelle: Profilseite auf medicana.com.tr

  34. Alan O, Akin Telli T, Ercelep O, Tanrikulu Simsek E, Basoglu Tuylu T, Mutis A, Hasanov R, Kaya S, Akgul Babacan N, Dane F, Yumuk P Fulden (2018). Chordoma: a case series andreview of the literature. Journal of Medical Case Reports, 12:239.

    Quelle: Profilseite auf medicana.com.tr

  35. Bahceci A, Seker M M, Kacan T, Akgul Babacan N, Yucel B, Gedikli A. Sunitinib induced cytopenia in metastatic RCC (2018). Clin Med Rev Case Rep, 5:208.

    Quelle: Profilseite auf medicana.com.tr

  36. Alan, O., Ercelep, O., Telli, T. A., Tuylu, T. B., Önes, T., Bozkurtlar, E., NA Babacan ... & Kaya, S. (2018). P3. 16-48 Is Preoperative SUV (Max) of Primary Tumor a Predictor of Relapse for Operable Non-Small Cell Lung Cancer?. Journal of Thoracic Oncology, 13(10), S1020.

    Quelle: Profilseite auf medicana.com.tr

  37. Karadurmus N., Sendur M. A. N., Karaca B., Olmez O. F., Hacibekiroglu I., Coskun H. S., Degirmencioglu S., Kemal Y., Kilickap S., Sumbul A. T., Aydin B., Turna H., Kaplan M. A., Babacan N., Demirci U., Ata A., Erdem D., Ozet A., Abali H. (2018). Experience from Turkish centers participating in the early access program (EAP): preliminary real world safety data of nivolumab (nivo) combined with ipilimumab (ipi) in pre-treated advanced melanoma patients. Journal of Oncological Science, https://doi.org/10.1016/j.jons.2018.10.001

    Quelle: Profilseite auf medicana.com.tr

  38. Imeryuz, N., Atug, O., Kani, H. T., Alahdab, Y. O., Demirtas, C. O., Ozkan Gulsoy, H., O Ercelep, AE Atıcı, R Ergelen, IE Seven, NA Babacan... & Yemisci, I. (2019). Treatment of Hermansky-Pudlak syndrome Associated granulomatous colitis with anti-TNF agents: case series and review of literature.

    Quelle: Profilseite auf medicana.com.tr

  39. Babacan, Nalan A., and Tawee Tanvetyanon. Superimposed Clostridium Difficile Infection During Checkpoint Inhibitor Immunotherapy-induced Colitis (2019). Journal of Immunotherapy, 42(9), 350-353

    Quelle: Profilseite auf medicana.com.tr

  40. Smalley, I., Kim, E., Li, J., Spence, P., Wyatt, C. J., Eroglu, Z., VK Sondak, JL Messina, NA Babacan... & De Armas, L. (2019). Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma. EBioMedicine, 48, 178-190.

    Quelle: Profilseite auf medicana.com.tr

  41. Tuylu, T. B., Demircan, N. C., Arikan, R., Telli, T. A., Alan, O., Ercelep, O., F Dane, MA Ozturk, NA Babacan… - ... & Lacin, T. (2019). P2. 06-22 Is Laboratory Prognostic Index a Valuable Prognostic Index for Malignant Pleural Mesothelioma?. Journal of Thoracic Oncology, 14(10), S763.

    Quelle: Profilseite auf medicana.com.tr

  42. Ercelep, O., Alan, O., Sahin, D., Telli, T. A., Salva, H., Tuylu, T. B., NA Babacan... & Alkis, H. (2019). Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer. Clinical and Translational Oncology, 21(4), 499-504. doi: 10.1007/s12094-018-1949-6.

    Quelle: Profilseite auf medicana.com.tr

  43. Demircan, N. C., Dane, F., Ozturk, M. A., Babacan, N. A., Besiroglu, M., Kaya, S., ... & Alan, O. (2019). Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy. Liver, 232, 64-4.

    Quelle: Profilseite auf medicana.com.tr

  44. Ercelep, Ö., Telli, T. A., Özkan, A. L. A. N., Hasanov, R., Şimşek, E. T., Babacan, N. A., ... & Yumuk, P. F. (2020). Smokers having Activating EGFR Mutant Non-Small Cell Lung Cancer Might Benefit from EGFR-TKI Treatment? Single-Center Experience. Turkısh Journal Of Oncology, 1(3).

    Quelle: Profilseite auf medicana.com.tr

  45. Demircan, N. C., Alan, Ö., Başoğlu Tüylü, T., Akın Telli, T., Arıkan, R., Çiçek, F. C., R Ergelen, I Tinay, N Akgül Babacan ... & P F Yumuk. (2020). Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib. Journal of Oncology Pharmacy Practice, 26(5), 1147-1155.

    Quelle: Profilseite auf medicana.com.tr

  46. Alan, O., Kuzhan, O., Koca, S., Telli, T. A., Basoglu, T., Ercelep, O., ... & Babacan, N. A. (2020). How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature. Journal of Oncology Pharmacy Practice, 26(4), 1011-1018.

    Quelle: Profilseite auf medicana.com.tr

  47. Eroglu, Z., Eatrides, J., Naqvi, S. M. H., Kim, Y., Rich, J., Babacan, N. A., ... & Khushalani, N. I. (2020). Neoadjuvant BRAF‐targeted therapy in regionally advanced and oligometastatic melanoma. Pigment Cell & Melanoma Research, 33(1), 86-95.

    Quelle: Profilseite auf medicana.com.tr

  48. Alan, O., Telli, T. A., Aktas, B., Koca, S., Ökten, I. N., Hasanov, R., MU Ugurlu, H Kaya, NA Babacan... & Kaya, S. (2020). Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment?. World Journal of Surgical Oncology, 18(1), 1-9.

    Quelle: Profilseite auf medicana.com.tr

  49. Babacan, N. A., Pina, I. B., Signorelli, D., Prelaj, A., Garassino, M. C., & Tanvetyanon, T. (2020). Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis. Clinical Lung Cancer, 21(5), e456-e463.

    Quelle: Profilseite auf medicana.com.tr

  50. Demirelli, B., Babacan, N. A., Ercelep, Ö., Öztürk, M. A., Kaya, S., Tanrıkulu, E., ... & Koca, S. (2020). Modified Glasgow Prognostic Score, Prognostic Nutritional Index and ECOG Performance Score Predicts Survival Better than Sarcopenia, Cachexia and Some Inflammatory Indices in Metastatic Gastric Cancer. Nutrition and Cancer, 1-9.

    Quelle: Profilseite auf medicana.com.tr